The Surprising Impact of Drug Price Negotiation on Clinical Trials

Why It Matters

The study shows Medicare price negotiations can dampen R&D at targeted firms without collapsing overall innovation, underscoring the need for vigilant monitoring as the policy expands.

Key Takeaways

• Overall industry‑wide trial initiations stayed stable after negotiation.
• Firms subject to price cuts reduced new clinical trial launches.
• Non‑negotiated companies filled the gap, keeping aggregate activity flat.
• Early pipeline signals, not approvals, reveal policy’s innovation impact.
• Continuous monitoring needed as future rounds expand to more drugs.

Summary

The podcast examines a new Health Affairs paper that tracks how the Inflation Reduction Act’s Medicare drug‑price negotiation provision has affected biopharmaceutical clinical‑trial activity. Dr. So Young Kang and co‑authors compare industry‑sponsored trial initiations from 2015‑2024, focusing on firms directly hit by the negotiation list versus those that are not.

Their analysis shows that, at the aggregate level, trial initiations rebounded to pre‑pandemic levels and did not plunge after the policy’s rollout, suggesting no immediate industry‑wide innovation cliff. However, companies whose products were selected for price negotiation launched fewer new trials, while firms outside the negotiation pool maintained or increased activity, effectively offsetting the decline in the overall count.

Kang emphasizes that the policy removed uncertainty for firms facing price cuts, prompting them to adjust long‑range R&D budgeting years in advance. She likens early‑stage trial decisions to “calories in the coal mine,” an early warning signal of future innovation health. The discussion also highlights the need to track pre‑clinical funding, seed investments, and pipeline shifts as the negotiation program expands.

The findings suggest a nuanced impact: price negotiations do not halt innovation across the sector, but they do reshape R&D behavior among directly affected companies. Policymakers and investors should therefore monitor early‑stage pipeline metrics as future negotiation rounds broaden, balancing affordability goals with sustained drug development.

Original Description

Health Affairs' Rob Lott interviews So-Yeon Kang of Georgetown University about her recent paper exploring trends in biopharmaceutical clinical trials after The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices for selected drugs.

---

Visit Health Affairs: http://www.healthaffairs.org

Subscribe and Listen to our Podcasts: https://www.healthaffairs.org/podcasts

Sign up for our free Newsletters: https://www.healthaffairs.org/newsletters